{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:55:28Z","timestamp":1790870128979,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,1]],"date-time":"2027-10-01T00:00:00Z","timestamp":1822348800000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS100947"],"award-info":[{"award-number":["R01NS100947"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS136070"],"award-info":[{"award-number":["R21NS136070"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R61\/R33NS130199"],"award-info":[{"award-number":["R61\/R33NS130199"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tips.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:36:34Z","timestamp":1789187794000},"page":"1186-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Centanafadine (Simtriyo): a triple monoamine reuptake inhibitor for ADHD"],"prefix":"10.1016","volume":"47","author":[{"given":"Juqian","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssia Antwania","family":"Pruitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-8928","authenticated-orcid":false,"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.08.011_bb0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/syn.21538","article-title":"Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder","volume":"66","author":"Bymaster","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.tips.2026.08.011_bb0010","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2147\/NDT.S242084","article-title":"Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies","volume":"16","author":"Wigal","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.tips.2026.08.011_bb0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder","volume":"128","author":"Faraone","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2026.08.011_bb0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/JCP.0000000000001575","article-title":"Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials","volume":"42","author":"Adler","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.tips.2026.08.011_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/02698811221140008","article-title":"Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: a phase 1 study in healthy male adults","volume":"37","author":"Matuskey","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2026.08.011_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13052-023-01456-1","article-title":"The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis","volume":"49","author":"Salari","year":"2023","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.tips.2026.08.011_bb0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41586-024-07796-0","article-title":"Dopamine reuptake and inhibitory mechanisms in human dopamine transporter","volume":"632","author":"Li","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.08.011_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2025.106275","article-title":"Role of serotonin in psychiatric and somatic comorbidities of attention-deficit\/hyperactivity disorder: a systematic literature review","volume":"176","author":"Faraone","year":"2025","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2026.08.011_bb0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40261-025-01473-4","article-title":"Revisiting the role of serotonin in attention-deficit hyperactivity disorder: new insights from preclinical and clinical studies","volume":"45","author":"Solomon","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.tips.2026.08.011_bb0050","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jaac.2025.06.023","article-title":"Centanafadine for attention-deficit\/hyperactivity disorder in adolescents: a randomized clinical trial","volume":"65","author":"Ward","year":"2026","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:07:12Z","timestamp":1790867232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726002087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0165614726002087"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.08.011","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Centanafadine (Simtriyo): a triple monoamine reuptake inhibitor for ADHD","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}